DANIEL’S BENLYSTA TREATMENT

Hypothetical patient profile. May not be
representative of all patients.

  • TRANSCRIPT

    DANIEL: I still had protein in my urine and started having butterfly rash. So, my doctor and I discussed about adding BENLYSTA to my treatment. I first got started on BENLYSTA infusions for a couple of months and when my doctor shared that I could switch to the injections at home once a week if I preferred, that was great news; that sounded pretty good to me. He was confident that BENLYSTA could help improve my lupus and lupus nephritis.

    ON-SCREEN TEXT: Daniel’s current therapy: BENLYSTA IV for 8 weeks; 10 mg/kg administered every 2 weeks for the first 3 doses and every 4 weeks thereafter; Switched to BENLYSTA SC* – 200 mg once per week; Mycophenolate mofetil (MMF): 2 g/day orally; Prednisone: 7.5 mg/day; Hydroxychloroquine: 300 mg/day.

    ON-SCREEN TEXT: * Patients with SLE: Administer the first subcutaneous dose 1 to 4 weeks after the last intravenous dose. IV and SC are not to be used concurrently. Patients with lupus nephritis: Transition to subcutaneous therapy can be done any time after the patient completes the first 2 intravenous doses. Administer the first subcutaneous dose 1 to 2 weeks after the last intravenous dose. IV and SC are not to be used concurrently.

    DANIEL: It’s now been a few months since I first started on BENLYSTA, and it seems to be working well. My kidney function has improved, and I’ve been able to lower my steroid dose.

    ON-SCREEN TEXT: Results may vary.

    DANIEL: I appreciate the option of the Autoinjector. And I love the once-weekly dosing with at-home convenience. I’m always running around with the kids, so it’s very comforting to know that I can take my injection at home.

    ON-SCREEN TEXT: Trademarks owned or licensed by GSK. BELVID210026 September 2021.

You may also like

SEE DANIEL’S
DIAGNOSIS STORY
REVIEW DANIEL’S
INITIAL TREATMENT

Hypothetical patient profile. May not be
representative of all patients.